Omthera Pharmaceuticals, which has developed a prescription fish oil capsule that reduces triglyceride levels, raised $64 million by offering 8.0 million shares at $8, well below the range of $12 to $14. Omthera, which initially filed confidentially on 1/25/2013, plans to list on the NASDAQ under the symbol OMTH. BofA Merrill Lynch, Barclays and Leerink Swann acted as lead managers on the deal.
